DOCSLIB.ORG

Desensitization of 5-HT1A Autoreceptors by a Low Chronic Fluoxetine Dose Effect of the Concurrent Administration of WAY-100635 Ildefonso Hervás, Ph.D., M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Desensitization of 5-HT1A Autoreceptors by a Low Chronic Fluoxetine Dose Effect of the Concurrent Administration of WAY-100635 Ildefonso Hervás, Ph.D., M View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Digital.CSIC Desensitization of 5-HT1A Autoreceptors by a Low Chronic Fluoxetine Dose Effect of the Concurrent Administration of WAY-100635 Ildefonso Hervás, Ph.D., M. Teresa Vilaró, Ph.D., Luz Romero, Ph.D., M. Cecilia Scorza, M.D., Guadalupe Mengod, Ph.D., and Francesc Artigas, Ph.D. Using microdialysis, receptor autoradiography and in situ autoreceptors, an effect prevented by the concurrent WAY- hybridization, we examined the effects of fluoxetine alone or 100635 administration. However, WAY-100635 (alone or with WAY-100635 on: (a) extracellular 5-HT in frontal with fluoxetine) did not change 5-HT1A autoreceptor cortex; and (b) density and sensitivity of 5-HT1A sensitivity. The density of 5-HT1A receptors and its encoding autoreceptors in rat brain. WAY-100635 (0.3 mg/kg, s.c.) mRNA, was unaffected by these treatments. These results doubled the increase in extracellular 5-HT produced by suggest that prolonged blockade of 5-HT1A receptors in vivo fluoxetine (3 mg/kg, i.p.) in frontal cortex. Two-week prevents the autoreceptor desensitization induced by minipump treatments with these daily doses significantly fluoxetine but does not result in receptor sensitization. raised extracellular 5-HT to 275 Ϯ 33% (fluoxetine) and [Neuropsychopharmacology 24:11–20, 2001] © 2000 245 Ϯ 10% (fluoxetine plus WAY-100635) of controls. American College of Neuropsychopharmacology. Published Fluoxetine 3 mg/kg·day desensitized dorsal raphe 5-HT1A by Elsevier Science Inc. KEY WORDS: 5-hydroxytryptamine uptake; 5-HT1A receptors; anism with 5-HT1A receptor antagonists augments the Dorsal raphe nucleus; Frontal cortex; Microdialysis; neurochemical and behavioral effects of SSRIs (Gartside Selective serotonin reuptake inhibitors (SSRI) et al. 1995; Artigas et al. 1996; Hashimoto et al. 1997; Selective serotonin (5-hydroxytryptamine, 5-HT) re- Mitchell and Redfern 1997; Grignaschi et al. 1998; Trillat ␤ uptake inhibitors (SSRIs) are extensively used in the et al. 1998). At the clinical level, the -adrenoceptor/ treatment of major depression. The increase in fore- 5-HT1A receptor antagonist pindolol accelerates the an- brain extracellular 5-HT elicited by SSRIs is limited by a tidepressant effects of SSRIs in open-label and placebo- negative feed-back involving raphe autoreceptors (Arti- controlled trials (Artigas et al. 1994; Blier and Bergeron gas et al. 1996). The prevention of this inhibitory mech- 1995; Pérez et al. 1997; Zanardi et al. 1997, 1998; Bordet et al. 1998). However, its effectiveness to potentiate an- tidepressant response in chronically ill or treatment- From the Department of Neurochemistry, Instituto de Investiga- resistant patients is still controversial (Maes et al. 1996, ciones Biomédicas de Barcelona (CSIC), IDIBAPS, Barcelona, Spain. 1999; Berman et al. 1997; Moreno et al. 1997; Pérez et al. M. Cecilia Scorza permanent address: Instituto Clemente Estable, Montevideo, Uruguay. 1999). Based on this rationale, selective 5-HT1A receptor Address correspondence to: Francesc Artigas, Department of Neu- antagonists (for use with SSRIs; add-on strategy) and rochemistry, Instituto de Investigaciones Biomédicas de Barcelona dual action compounds (5-HT reuptake inhibitor ϩ 5-HT (CSIC), IDIBAPS, Rosselló, 161, 6th floor, 08036 Barcelona, Spain. 1A Received 13 April 2000; revised 19 May 2000; accepted 30 June antagonist) are being developed for use in the treat- 2000. ment of major depression. NEUROPSYCHOPHARMACOLOGY 2001–VOL. 24, NO. 1 © 2000 American College of Neuropsychopharmacology Published by Elsevier Science Inc. 0893-133X/01/$–see front matter 655 Avenue of the Americas, New York, NY 10010 PII S0893-133X(00)00175-5 12 I. Hervás et al. NEUROPSYCHOPHARMACOLOGY 2001–VOL. 24, NO. 1 The prolonged administration of SSRIs has been re- Dialysate samples of 5 ␮l were collected at 20-min in- ported to desensitize raphe 5-HT1A autoreceptors, as as- tervals into polypropylene microcentrifuge vials. After sessed by single unit recordings and brain microdialy- an initial 1-h sample of dialysate was discarded, four to sis (Blier and de Montigny 1994; Invernizzi et al. 1994; six fractions were collected to obtain basal values before Arborelius et al. 1995; Le Poul et al. 1995). This reduces drug administration. At the end of the experiments, rats the efficacy of the above negative feedback and in- were killed by an overdose of sodium pentobarbital and creases extracellular 5-HT (Bel and Artigas 1993; Inv- the placement of the dialysis probes was checked by ernizzi et al. 1994; Rutter et al. 1994; Arborelius et al. perfusing Fast Green dye and examination of the probe 1996). Other studies, however, have failed to observe track after cutting the brain at the appropriate level. such effects even using large doses of SSRIs (Hjorth and 5-HT was analyzed by a modification of a high per- Auerbach 1994a; Auerbach and Hjorth 1995; Bosker et formance liquid chromatography method previously al. 1995; Invernizzi et al. 1995). described (updated in Adell and Artigas 1998). 5-HT To our knowledge, there are no published reports on was separated on a 3 ␮m ODS 2 column (7.5 cm ϫ 0.46 the effects of prolonged treatments with combinations cm; Beckman, San Ramon, CA) and detected ampero- of SSRIs and 5-HT1A receptor antagonists on these ex- metrically with a Hewlett Packard 1049 detector set at perimental paradigms, except in abstract form (Dawson the potential of ϩ0.6V. Retention time was 3.5–4 min. et al. 1998). As with pindolol, future selective 5-HT1A re- The detection limit for 5-HT was typically 0.5–1 fmol/ ceptor antagonists would be administered for a limited sample. Dialysate 5-HT values were calculated by refer- period of time. Should prolonged blockade of 5-HT1A ence to standard curves run daily. receptor result in receptor sensitization, the withdrawal of the antagonist would increase the efficacy of the Treatments above negative feed-back and reduce the ability of the SSRI to increase extracellular 5-HT, thus increasing the possi- Four different experiments were conducted. In the first bility of a clinical relapse. Since this is crucial for the one, we examined the effects on extracellular 5-HT in success of this therapeutic strategy, we examined the ef- frontal cortex of single doses of fluoxetine (3 mg/kg, i.p.) fects of two-week treatments with fluoxetine, WAY- plus (20 min later) saline or WAY-100635 [N-(2-(4-(2- 100635 and their combination on the labeling and sensi- methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl) и tivity of 5-HT1A autoreceptors in rat brain . cyclohexanecarboxamide 3HCl] (RBI, Natick, MA) (0.3 mg/kg, s.c.). A second experiment assessed the effect of two-week minipump treatments with fluoxetine (3 mg/ METHODS kg·day) and fluoxetine plus WAY-100635 (0.3 mg/ kg·day) on the basal extracellular 5-HT concentration. In Microdialysis Procedures this group, microdialysis experiments were conducted on Male Wistar rats (280–300 g; Iffa-Credo, Lyon, France) the 14th day of treatment, with the minipump on board. were used. Animal care followed the European Union In a third experiment, the same treatments (fluoxe- regulations (O.J. of E.C. L358/1 18/12/1986). A de- tine 3 mg/kg·day and fluoxetine 3 mg/kg·day plus tailed description of the microdialysis procedures can WAY-100635 0.3 mg/kg·day) were given but minipumps be found in Adell and Artigas (1998). Briefly, anesthe- were removed under light anesthesia on day 14th and tized rats (pentobarbital, 60 mg/kg, i.p.) were placed in microdialysis experiments were conducted two days a David Kopf (Tujunga, CA) stereotaxic frame. Concen- later to examine the labeling and sensitivity of 5-HT1A tric dialysis probes (4.0 mm long) were implanted in receptors. A complete washout of fluoxetine was ex- frontal cortex and secured to the skull with anchor pected at this time, as judged from its complete elimina- screws and dental cement. Dialysis membranes were tion in two days from the brain compartment after 21- made from hollow Cuprophan fibers with 252 ␮m OD, day treatments with higher doses (10–30 mg/kg·day) 220 ␮m ID, and 5000-dalton molecular weight cutoff (Gardier et al. 1993). In these experimental groups, dial- (GFE09; Gambro, Lund, Sweden). ysis probes were perfused with an artificial CSF contain- The stereotaxic coordinates (in mm; AP ϩ3.4, DV ing 1 ␮M citalopram. In this experimental condition, the Ϫ6.0, L Ϫ2.5) were taken from bregma and dura mater systemic administration of SSRIs reduces extracellular according to the rat brain atlas of Paxinos and Watson 5-HT due to the activation of somatodendritic 5-HT1A (1986). Rats were allowed to recover from anesthesia in autoreceptors (see Discussion). With the same time the dialysis cages (cubic, 40 cm each side) and 20–24 h schedule (two-week treatment plus two-day washout) later the probes were perfused with artificial CSF and experimental conditions, a fourth experiment exam- (aCSF; composition: NaCl 125 mM, KCl 2.5 mM, MgCl2 ined the effect of WAY-100635 (0.3 mg/kg·day) alone on ␮ 1.18 mM, and CaCl2 1.26 mM; pH 6.5–7.0) at 0.25 l/ the sensitivity of raphe 5-HT1A receptors. Control rats in min. In some experiments, the aCSF was supplemented all groups received the corresponding vehicle for the with 1 ␮M of the SSRI citalopram. same time periods. NEUROPSYCHOPHARMACOLOGY 2001–VOL. 24, NO. 1 Fluoxetine, WAY-100635, and 5-HT1A Receptors 13 In chronic experiments, rats were implanted s.c. with Data Treatment Alzet 2002 minipumps filled to deliver vehicle (water/ Dialysate 5-HT concentrations are expressed as fmol/ dimethyl sulfoxide 50/50%), fluoxetine 3 mg/kg·day fraction and represented in some figures as percentage (Eli Lilly and Co., Indianapolis, IN), WAY-100635 0.3 of baseline (average of four pre-drug fractions).
Load more

Recommended publications
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
    [Show full text]
  • Regulation of Neuronal Communication by G Protein-Coupled Receptors ⇑ Yunhong Huang, Amantha Thathiah
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 589 (2015) 1607–1619 journal homepage: www.FEBSLetters.org Review Regulation of neuronal communication by G protein-coupled receptors ⇑ Yunhong Huang, Amantha Thathiah VIB Center for the Biology of Disease, Leuven, Belgium Center for Human Genetics (CME) and Leuven Institute for Neurodegenerative Diseases (LIND), University of Leuven (KUL), Leuven, Belgium article info abstract Article history: Neuronal communication plays an essential role in the propagation of information in the brain and Received 31 March 2015 requires a precisely orchestrated connectivity between neurons. Synaptic transmission is the mech- Revised 5 May 2015 anism through which neurons communicate with each other. It is a strictly regulated process which Accepted 5 May 2015 involves membrane depolarization, the cellular exocytosis machinery, neurotransmitter release Available online 14 May 2015 from synaptic vesicles into the synaptic cleft, and the interaction between ion channels, G Edited by Wilhelm Just protein-coupled receptors (GPCRs), and downstream effector molecules. The focus of this review is to explore the role of GPCRs and G protein-signaling in neurotransmission, to highlight the func- tion of GPCRs, which are localized in both presynaptic and postsynaptic membrane terminals, in reg- Keywords: G protein-coupled receptors ulation of intrasynaptic and intersynaptic communication, and to discuss the involvement of G-proteins astrocytic GPCRs in the regulation of neuronal communication. Neuronal communication Ó 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. Synaptic transmission Signaling Astrocytes Neurons Autoreceptors Neurotransmitters 1.
    [Show full text]
  • Antidepressant Potential of Nitrogen-Containing Heterocyclic Moieties: an Updated Review
    Review Article Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review Nadeem Siddiqui, Andalip, Sandhya Bawa, Ruhi Ali, Obaid Afzal, M. Jawaid Akhtar, Bishmillah Azad, Rajiv Kumar Department of ABSTRACT Pharmaceutical Chemistry, Depression is currently the fourth leading cause of disease or disability worldwide. Antidepressant is Faculty of Pharmacy, Jamia Hamdard approved for the treatment of major depression (including paediatric depression), obsessive-compulsive University, Hamdard disorder (in both adult and paediatric populations), bulimia nervosa, panic disorder and premenstrual Nagar, New Delhi - dysphoric disorder. Antidepressant is a psychiatric medication used to alleviate mood disorders, such as 110 062, India major depression and dysthymia and anxiety disorders such as social anxiety disorder. Many drugs produce an antidepressant effect, but restrictions on their use have caused controversy and off-label prescription a Address for correspondence: risk, despite claims of superior efficacy. Our current understanding of its pathogenesis is limited and existing Dr. Sandhya Bawa, E-mail: sandhyabawa761@ treatments are inadequate, providing relief to only a subset of people suffering from depression. Reviews of yahoo.com literature suggest that heterocyclic moieties and their derivatives has proven success in treating depression. Received : 08-02-11 Review completed : 15-02-11 Accepted : 17-02-11 KEY WORDS: Antidepressant, depression, heterocyclic epression is a chronic, recurring and potentially life- monoamine oxidase inhibitors (MAOIs, e.g. Nardil®) tricyclic D threatening illness that affects up to 20% of the population antidepressants (TCAs, e.g. Elavil). They increases the synaptic across the globe.[1] The etiology of the disease is suboptimal concentration of either two (5-HT and NE) or all three (5-HT, concentrations of the monoamine neurotransmitters serotonin NE and dopamine (DA)) neurotransmitters.
    [Show full text]
  • WO 2011/064769 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 3 June 2011 (03.06.2011) WO 201 1/064769 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 31/506 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/70 (2006.01) A61P 5/24 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IL20 10/000976 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 22 November 2010 (22.1 1.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/264,025 24 November 2009 (24.1 1.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): YIS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, SUM RESEARCH DEVELOPMENT COMPANY OF TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, THE HEBREW UNIVERSITY OF JERUSALEM EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, LTD.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • The Therapeutic Role of 5-HT1A and 5-HT2A Receptors in Depression
    CRSN Symposium: Focus on Depression, Part II Symposium du CRSN : le point sur la dépression, deuxième partie The therapeutic role of 5-HT1A and 5-HT2A receptors in depression Pau Celada, PhD; M. Victoria Puig, PhD; Mercè Amargós-Bosch, PharmD; Albert Adell, PhD; Francesc Artigas, PhD Department of Neurochemistry, Institut d’Investigacions Biomèdiques de Barcelona, Consejo Superior de Investigaciones Cientificas (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain. The selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed antidepressant drugs, because they are well tolerated and have no severe side effects. They rapidly block serotonin (5-HT) reuptake, yet the onset of their therapeutic action requires weeks of treatment. This delay is the result of presynaptic and postsynaptic adaptive mechanisms secondary to reuptake inhibition. The preven- tion of a negative feedback mechanism operating at the 5-HT autoreceptor level enhances the neuro- chemical and clinical effects of SSRIs. The blockade of 5-HT2A receptors also seems to improve the clinical effects of SSRIs. These receptors are located postsynaptically to 5-HT axons, mainly in the neocortex. Pyramidal neurons in the prefrontal cortex are particularly enriched in 5-HT2A receptors. Their blockade may affect the function of prefrontal–subcortical circuits, an effect that probably underlies the beneficial effects of the addition of atypical antipsychotic drugs, which are 5-HT2A receptor antagonists, to SSRIs in treatment-resistant patients. Les inhibiteurs spécifiques du recaptage de la sérotonine (ISRS) sont le plus souvent prescrits comme anti- dépresseurs parce qu’ils sont bien tolérés et ne produisent pas d’effets secondaires graves.
    [Show full text]
  • Theories of Depression by Richard H
    Theories of Depression by Richard H. Hall, 1998 Monamine/5-HT Hypothesis Just as with schizophrenia, the most popular neurophysiological theory of depression follows from the drugs that are used to treat it. The evolution of antidepressant drugs has, in some ways, been the systematic narrowing down of monoamines to Serotonin. MAO inhibitors are Dopamine-Epinephrine-Norephinephrine-Seratonin agonists. Tricyclic Antidepressants are Norepinephrine-Serotonin agonists, and, finally SSRIs act as Serotonin (5-HT) agonists. Thus, the monoamine hypothesis has evolved in the same way, so that today one popular theory of depression, the Monoamine Hypothesis, is that depression is the result of underactivity of monoamines, especially 5-HT. Besides the fact that antidepression drugs are all monoamine agonists, there is other evidence that supports the theory. First, Reserpine, a monoamine antagonist, which was used to treat things like high blood pressure, is rarely used at the present time due to the fact that depression is a common side effect. Thus, not only can monoamine agonists decrease depression, but monoamine antagonists (Reserpine) can induce depression. Another piece of evidence in support of the Monoamine Hypothesis is that levels of 5-HT, as measured by its metabolites, seem to be correlated with depression. For example, patients who have low levels of a 5-HT metabolite were found to be more likely to have committed suicide. It often takes two to three weeks for antidepressant drugs to effectively treat depression. This is a difficult phenomenon to explain within the context of the monoamine hypothesis. Presumably, in response to monoamine agonists these neurotransmitter levels increase right away, and, if depression is caused by low levels of the neurotransmitter, then depression should decrease as the levels of monoamines increase.
    [Show full text]
  • Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain
    Neuropsychopharmacology (2009) 34, 651–661 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain ,1 1 1,2 O Chernoloz* , M El Mansari and P Blier 1 2 Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ontario, Canada Pramipexole (PPX) is a D2/D3 receptor agonist that has been shown to be effective in the treatment of depression. Serotonin (5-HT), norepinephrine (NE) and dopamine (DA) systems are known to be involved in the pathophysiology and treatment of depression. Due to reciprocal interactions between these neuronal systems, drugs selectively targeting one system-specific receptor can indirectly modify the firing activity of neurons that contribute to firing patterns in systems that operate via different neurotransmitters. It was thus hypothesized that PPX would alter the firing rate of DA, NE and 5-HT neurons. To test this hypothesis, electrophysiological experiments were carried out in anesthetized rats. Subcutaneously implanted osmotic minipumps delivered PPX at a dose of 1 mg/kg per day for 2 or 14 days. After a 2-day treatment with PPX the spontaneous neuronal firing of DA neurons was decreased by 40%, NE neuronal firing by 33% and the firing rate of 5-HT neurons remained unaltered. After 14 days of PPX treatment, the firing rate of DA had recovered as well as that of NE, whereas the firing rate of 5-HT neurons was increased by 38%.
    [Show full text]
  • Drugs, the Brain, and Behavior
    Drugs, The Brain, and Behavior John Nyby Department of Biological Sciences Lehigh University What is a drug? Difficult to define Know it when you see it Neuroactive vs Non-Neuroactive drugs Two major categories of neuroactive drugs: Therapeutic Drugs Recreational Drugs (Drugs of Abuse) Both types of neuroactive drugs affect neural functioning and behavior How does a drug affect behavior Drug Behavioral (Antidepressant) Outcome (Capable of positive emotions) Different Levels at which drug effects in the brain can be studied Molecular Cellular Organismal events Events Events “Good” Therapeutic Drugs vs “Bad” Addictive drugs No clear boundary! All “good” drugs have undesirable side effects Many “good” drugs can be addictive (i.e. “bad”) under the right circumstances (i.e. Rush Limbaugh and oxycontin) How does Drug Enforcement Administration (DEA) decide whether a drug is a “good” therapeutic drug or a “bad” illegal drug. A “bad” drug in the US can be a good drug in other countries Neuroactive Drugs Work by Altering Chemical Signaling in the Brain Two Classes of Chemical Signals in the brain Neurotransmitters Neurohormones Two Ways a Drug Affects Neural Signaling Agonist for chemical signal Antagonist for chemical Signal In order to understand drug action must have a good understanding of chemical signaling in brain Neuronal communication Three Ways that information is transmitted in a Neuron Synapse Neuron Most neuroactive drugs act by altering synaptic transmission Generalized Synapse (Major Drug Events) Most neurotransmitters are either AA, modified AA, or peptides Neurotransmitter Agonists Peptide Neurotransmitter Antagonists in vesicle 1. serve as precursors AA 1. block synthetic enzymes 2. block degradative enzymes in cytoplasm 2.
    [Show full text]
  • 5-HT Receptors in Depressed Patients
    5-HT1A receptors in depressed patients: Evidence from PET, post mortem and EEG based studies R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional Affective Disorders Service, RVI 5-HT1A receptor distribution in the human brain Post synaptic receptors 2 Postsynaptic 5-HT1A receptors and depression • Function: – Prolactin and growth hormone responses to intravenous l-tryptophan • Blunted responses in depressed subjects in 5 studies1 • Number of receptors: – PET scanning of WAY-100635 binding • 10-30% decrease in binding in depressed2-5 and remitted depressed6 patients 1. Power and Cowen, 1992 Molec. Aspects Med. 13(3):205-220 2. Drevets et al. 1999 Biological Psychiatry 46:1375-1387 3. Sargent et al. 2000 Archives of General Psychiatry 57:174-180 4. Meltzer et al. 2004 Neuropsychopharmacology 29:2258-2265 5. Drevets et al. 2007 Nuclear Medicine & Biology 34:865-877 6. Bhagwagar et al. 2004 Molecular Psychiatry 9: 386-392 5-HT1A receptor binding across brain regions healthy controls () and MDD () 9 to 24% reduction in 5-HT1A binding across regions of interest in MDD Hirvonen et al. (2008) Int J Neuropsychopharm 11:465–476 5-HT1A receptor distribution in the human brain Post synaptic receptors Somatodendritic autoreceptors 5 5-HT1A receptor binding across brain regions healthy controls () and MDD () 9 to 24% reduction in 5-HT1A binding across regions of interest in MDD Hirvonen et al. (2008) Int J Neuropsychopharm 11:465–476 5-HT1A receptor binding – possible effect of antidepressant exposure Parsey et al. 2006 Biological Psychiatry 59:106 - 113 Replicated in new cohort: Parsey et al.
    [Show full text]
  • Are Nicotinic Acetylcholine Receptors Coupled to G Proteins?
    Insights & Perspectives Hypotheses Are nicotinic acetylcholine receptors coupled to G proteins? Nadine Kabbani1)*, Jacob C. Nordman1), Brian A. Corgiat1), Daniel P. Veltri2), Amarda Shehu2), Victoria A. Seymour3) and David J. Adams3) It was, until recently, accepted that the two classes of acetylcholine (ACh) synaptic plasticity [2, 3]. Mutations receptors are distinct in an important sense: muscarinic ACh receptors within nAChR genes are implicated signal via heterotrimeric GTP binding proteins (G proteins), whereas in a number of human disorders þ 2þ þ including drug addiction and schizo- nicotinic ACh receptors (nAChRs) open to allow flux of Na ,Ca ,andK phrenia [4]. ions into the cell after activation. Here we present evidence of direct coupling Nicotinic receptors belong to an between G proteins and nAChRs in neurons. Based on proteomic, evolutionarily conserved class of cys- biophysical, and functional evidence, we hypothesize that binding to G loop containing receptor channels that proteins modulates the activity and signaling of nAChRs in cells. It is includes GABAA,glycine,and5HT3 important to note that while this hypothesis is new for the nAChR, it is receptorsaswellastwonewlydiscovered channels: a zinc-activated channel and consistent with known interactions between G proteins and structurally an invertebrate GABA-gated cation chan- related ligand-gated ion channels. Therefore, it underscores an evolution- nel [5]. In mammals, genes encoding arily conserved metabotropic mechanism of G protein signaling via nAChR neuronal nAChR subunits have been channels. identified and labeled a (a1–a10) and b (b1–b4). Functional nAChRs are derived Keywords: from an arrangement of five subunits into .acetylcholine; G protein coupling; intracellular loop; ligand-gated ion channel; heteromeric or homomeric receptors [6] loop modeling; protein interaction; signal transduction (Fig.
    [Show full text]
  • Dawson, S., Maund, E., Stuart, B., Moore, M., Christopher, D
    Dawson, S. , Maund, E., Stuart, B., Moore, M., Christopher, D., Geraghty, A. WA., & Kendrick, T. (2019). Managing Antidepressant Discontinuation: A Systematic Review. Annals of Family Medicine, 17(1), 52-60. https://doi.org/10.1370/afm.2336 Peer reviewed version License (if available): Other Link to published version (if available): 10.1370/afm.2336 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via the Annals of Family Medicine at https://doi.org/10.1370/afm.2336 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Supplemental materials for: Maund E, Stuart B, Moore M, et al. Managing antidepressant discontinuation: a systematic review. Ann Fam Med. 2019;17(1):52-60. 1 Supplemental APPENDIX 1 - SEARCH STRATEGIES MEDLINE Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 23 March 2017 Search Query Items ID# found 1 exp ANTIDEPRESSIVE AGENTS/ 133782 2 exp NEUROTRANSMITTER UPTAKE INHIBITORS/ 133192 3 (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 136112 noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*).ti,kf,hw.
    [Show full text]